Clinical Trial: A 2-Year Study of an Investigational Drug in Obese Patients


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

A 2-Year Study of an Investigational Drug in Obese Patients

This study is no longer recruiting patients.

Sponsored by:	Merck
Information provided by:	Merck

Purpose

This is a 2-year study to assess the safety, tolerability, and efficacy of an investigational drug in obese patients.

Condition	Treatment or Intervention	Phase
Obesity		Phase II Phase III

MedlinePlus related topics: Obesity

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Eligibility

Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both

Criteria

Inclusion Criteria:

Obese men and nonpregnant women at least 18 years of age with a specific body mass index (height and weight ratio) required by the study

Exclusion Criteria:

Patients with uncontrolled high blood pressure and/or diabetes mellitus (high blood sugar)

More Information

Study ID Numbers: 2004_030
Record last reviewed: September 2004
Record first received: September 23, 2004
ClinicalTrials.gov Identifier: NCT00092859
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-10-22

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services